07:00 , Jul 14, 2016 |  BC Extra  |  Company News

Juno gets ADORA2A inhibitor in RedoxTherapies takeout

Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in upfront cash and undisclosed milestones. The deal gives Juno vipadenant (V2006), a small molecule adenosine A2A receptor (ADORA2A) antagonist. Juno said vipadenant...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Addex, Viva Biotech deal

Addex partnered with Viva Biotech to develop oral small molecule positive allosteric modulators (PAMs) of the adenosine A2 receptor (ADORA2) to treat inflammatory diseases, such as Huntington's disease (HD) and sickle cell disease. Viva Biotech...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Adenosine A2 receptor (ADORA2) In vitro and mouse studies suggest ADORA2 agonist-treated dendritic cells (DCs) could help treat acute kidney injury. Mice...
08:00 , Oct 30, 2006 |  BC Week In Review  |  Clinical News

ATL146e: Phase Ib started

Adenosine began a 2-part, double-blind, placebo-controlled, dose-escalation U.S. Phase Ib trial in up to 30 healthy volunteers. Adenosine Therapeutics LLC , Charlottesville, Va.   Product: ATL146e   Business: Inflammation   Molecular target: Adenosine A2 receptor...
07:00 , Jun 19, 2006 |  BioCentury  |  Strategy

Behind Ranexa

Behind Ranexa Behind Ranexa Although expanded and new indications for marketed angina drug Ranexa are the most advanced projects in CV Therapeutics’ pipeline, the company has eight additional projects spanning preclinical development to Phase III...
07:00 , Oct 6, 2003 |  BC Week In Review  |  Clinical News

VR2006: Phase I

BBG said it will start this year a Phase I trial. BBG obtained the compound through its September merger with Vernalis Group plc. Vernalis (LSE:BBG; BBIOY), Oxford, U.K.   Product: VR2006   Business: Neurology  ...
08:00 , Oct 30, 2000 |  BioCentury  |  Tools & Techniques

Receptor modulators in development

Receptor modulators in development Company Product Description Status AstraZeneca (AZN) NAD299 Serotonin 5HT1A receptor antagonist II AstraZeneca (AZN) AR-A2 Serotonin 5HT1B receptor antagonist Preclin Cephalon (CEPH) Provigil modafinil Alpha adrenergic receptor stimulant II Kyowa Hakko...
07:00 , Jul 31, 2000 |  BC Week In Review  |  Clinical News

KW-6002: Began Phase II trial

Kyowa Hakko Kogyo Co. Ltd., Tokyo, Japan   Product: KW-6002   Business: Neurological   Therapeutic category: Receptor antagonist   Target: Adenosine A2 receptors   Description: Adenosine A2 receptor antagonist   Indication: Treat depression   Status:...
08:00 , Nov 24, 1997 |  BC Week In Review  |  Company News

Roche, Kyowa Hakko Kogyo Co. Ltd. deal

Roche received exclusive worldwide marketing rights, excluding Japan, from Kyowa Hakko to an adenosine A2 receptor antagonist to treat Parkinson's disease. The companies will jointly develop the compound in Japan and will explore its use...